Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exicure, Inc.

< Previous 1 2 Next >
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Files Form 12b-25
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Present at Upcoming Scientific Conferences
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Present at Upcoming Scientific Conferences
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Present at the Benzinga Healthcare Small Cap Conference
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Participate in Upcoming Scientific Conferences
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure to Participate in Upcoming Investor Conferences
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress
From Exicure, Inc.
Via Business Wire
Tickers XCUR
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
From Exicure, Inc.
Via Business Wire
Tickers XCUR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.